| 1 |
t(15,17) bei AML FAB M3 (PML-RARA) |
Molecular Hemato-Oncology |
Molecular Hemato-Oncology |
| 2 |
t(5;12) bei CMML (ETV6-PDGFRB PCR) |
Molecular Hemato-Oncology |
Molecular Hemato-Oncology |
| 3 |
t(8,21) bei AML FAB M2 (RUNX1-RUNX1T1) |
Molecular Hemato-Oncology |
Molecular Hemato-Oncology |
| 4 |
T-cell receptor ( alpha/beta ) |
T-/NK-Cell Marker |
CSF |
| 5 |
T-cell receptor ( gamma/delta ) |
T-/NK-Cell Marker |
CSF |
| 6 |
T-helper cells (CD3+CD4+) |
Lymphocyte-Differentiation |
CSF |
| 7 |
T-helper cells abs. |
Lymphocyte-Differentiation |
CSF |
| 8 |
T-helper cells V-beta CSF |
TCR-Differentiation (V-beta-chain-variants) |
CSF |
| 9 |
T-lymphocytes (CD 3+) |
Lymphocyte-Differentiation |
CSF |
| 10 |
T-Lymphocytes abs. |
Lymphocyte-Differentiation |
CSF |
| 11 |
T-suppr./cytotox. (CD3+CD8+) |
Lymphocyte-Differentiation |
CSF |
| 12 |
T-Suppr./cytotox. absolute |
Lymphocyte-Differentiation |
CSF |
| 13 |
T-Suppr./cytotox. V-beta CSF |
TCR-Differentiation (V-beta-chain-variants) |
CSF |
| 14 |
T4/T8 ratio |
Lymphocyte-Differentiation |
CSF |
| 15 |
T4/TBG ratio |
Thyroid gland |
Endocrinology |
| 16 |
TA-Repeat Promotor (UGT1A1) |
Molecular Genetics |
Molecular Genetics |
| 17 |
Tacrolimus (LC-MS/MS) |
Pharmaceutical Drugs |
Toxicology / Drugs |
| 18 |
Tamoxifen (LC-MS/MS) |
Pharmaceutical Drugs |
Toxicology / Drugs |
| 19 |
tandem duplication gene MLL |
Molecular Hemato-Oncology |
Molecular Hemato-Oncology |
| 20 |
Tantalum |
Electrolytes, rare elements |
Clinical Chemistry |
ar
